ライフサイエンスコーパス: readmission

1 ion, thromboembolic event, hemodialysis, and readmission).

2 n is associated with a higher rate of 30-day readmission.

3 and the composite of all-cause mortality or readmission.

4 ssociated with a higher likelihood of 30-day readmission.

5 ed were death and the composite of death and readmission.

6 s also associated with higher odds of 30-day readmission.

7 ns being the most common intervention during readmission.

8 ere was no significant difference for 30-day readmission.

9 likelihood of 30-day postoperative unplanned readmission.

10 ation, reintervention, early extubation, and readmission.

11 -day mortality, surgical site infection, and readmission.

12 stay > 10 days were the predictors of 30-day readmission.

13 , percutaneous drainage, length of stay, and readmission.

14 ncreased likelihood of an inpatient hospital readmission.

15 was from postacute care spending followed by readmission.

16 ociated with the risk-adjusted likelihood of readmission.

17 .523 for serious complication, and 0.559 for readmission.

18 sion) identified patients at high risk of HF readmission.

19 er, and not higher, rate of 30-day unplanned readmission.

20 remained significantly associated with fewer readmissions.

21 d health-related quality of life and reduces readmissions.

22 ions, ED visits, post-acute utilization, and readmissions.

23 ly lower 1-year all-cause and cardiovascular readmissions.

24 days post-TAVR), and 17 (2.3%) had multiple readmissions.

25 ileus, and shorter hospital stays with fewer readmissions.

26 no significant change in mortality or 90-day readmissions.

27 ency department visits, and 90-day unplanned readmissions.

28 ernal and fetal outcomes, and cardiovascular readmissions.

29 isit communication was associated with fewer readmissions.

30 significant risk factor for adhesion-related readmissions.

31 , .38-.86) were both associated with reduced readmissions.

32 (LOS), emergency department (ED) visits, and readmissions.

33 I, .18-.67) was associated with lower 90-day readmissions.

34 tly associated with risk of adhesion-related readmissions.

35 ry reduces the incidence of adhesion-related readmissions.

36 plications and severity, length of stay, and readmissions.

37 The program did not change trend in 30-day readmission (+0.19% readmissions/mo, P=0.554) and trend

38 7 days), 30% to death (2.5 days), and 12% to readmission (1.0 days).

39 n repair patients had higher rates of 90-day readmission (12.9% EVR versus 17.8% open; P<0.001) and a

40 2.1% [95% CI, -15.5% to 19.8%]), unscheduled readmission (14.3% vs 15.7%; adjusted difference, -1.3%

41 s 2.2% P=0.99), and a greater risk of 30-day readmission (16.0% versus 9.6%, P<0.0001).

42 telephone, 10.6% clinic, P=0.11), all-cause readmission (18.8% telephone, 20.6% clinic, P=0.30), and

43 o, 0.91 [95% CI, 0.88-0.95]), cardiovascular readmission (19.7% versus 22.9%; hazard ratio, 0.85 [95%

44 ts not experiencing a complication or 30-day readmission (1923/2573, 74.7%), low-value hospitals had

45 -value hospitals (P<0.001), driven by higher readmission ($3675 versus $2177, P=0.005), professional

46 : stroke was associated with lower all-cause readmission (40.4% versus 44.1%; hazard ratio, 0.91 [95%

47 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI,

48 argest components of spending variation were readmissions (44% of variation, or $2043 per episode), p

49 vs 5.4 d, P < 0.01) and had fewer unplanned readmissions (5.9% vs 14.6%, P < 0.001).

50 Of all readmissions, 5166 (7.6%) were readmitted within 7 days.

51 9]), and composite of all-cause mortality or readmission (56.0% versus 58.4%; hazard ratio, 0.96 [95%

52 04-1.10]), and higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI,

53 nificant differences in 30-day heart failure readmission (8.6% telephone, 10.6% clinic, P=0.11), all-

54 ant patients experienced higher incidence of readmissions (8.0% vs 3.5%), surgical complications (5.0

55 associated with initial reduction in 30-day readmission (-9.8%, P=0.0002) and 30-day mortality (-2.6

56 .01-1.03), and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]).

57 1.01 [95% CI, 0.99-1.03]), higher all-cause readmission (adjusted HR, 1.02; 95% CI, 1.01-1.03), and

58 d HR, 1.39 [95% CI, 1.23-1.56]) and hospital readmission (adjusted HR, 1.19 [95% CI, 1.11-1.27]) at 1

59 n group had reduced odds of 90-day all-cause readmission (adjusted odds ratio, 0.2; 95% confidence in

60 ion between prior opioid exposure and 30-day readmissions, adjusted for patient risk factors and proc

61 Reducing hospital readmission after acute myocardial infarction (AMI) has

62 As such, readmission after AMI has been a target of financial pen

63 or acute myocardial infarction [AMI], 30-day readmission after AMI, and 30-day mortality after AMI) w

64 and factors associated with all-cause 30-day readmission after hospitalization for SCC.

65 the associations between early discharge and readmission after major abdominal operations.

66 ardiopulmonary complications, mortality, and readmission after noncardiac surgery.

67 n readmission diagnoses for 30-day and 7-day readmissions after discharge.

68 posure are associated with increased risk of readmissions after surgery.

69 Moreover, number of early readmission, age > 64 years, non-alcoholic cirrhosis, an

70 rtion of spending attributable to admission, readmission, ambulatory or emergency care; monthly spend

71 We developed a predictive model of 30-day readmission among hospitalized patients discharged on OP

72 In 2016, readmission among patients with SCC incurred an addition

73 dy was to characterize frequency of hospital readmissions among patients hospitalized with laboratory

74 as utilized clinical information to forecast readmissions, analyzing digital footprints from social m

75 We estimated the relative risk of 30-day readmission and 30-day mortality following an index hosp

76 ology care is associated with reduced 30-day readmission and 30-day mortality.

77 We evaluated the effect on 30-day readmission and death of follow-up within 7 days postdis

78 which malaria is endemic have a high risk of readmission and death within 6 months after discharge.

79 HF therapies at discharge on the risk of HF readmission and death.

80 were performed to identify predictors of HF readmission and death.

81 s designed to examine the temporal trends of readmission and mortality after AMI and HF in Ontario, C

82 hospitals, is associated with postdischarge readmission and mortality outcomes, and meaningfully rec

83 trointestinal bleeding, pump thrombosis, and readmission and reduced hazards for cardiac transplantat

84 Rates of HF readmissions and all-cause mortality were then compared

85 stained increases in spending due to greater readmissions and ambulatory care visits.

86 The associations between readmissions and area deprivation index were explored us

87 Among 7 studies that examined hospital readmissions and avoidable initial hospitalizations, non

88 Outcomes included 30-day readmissions and death and frequency and type of complet

89 dary (PR referral and completion) or safety (readmissions and death) endpoints.

90 There is a high rate of readmissions and deaths in the immediate 6 months after

91 SA children with BWF had increased risk of readmissions and deaths in the postdischarge period.

92 r primary aim was to study the rate of early readmissions and its predictors in liver transplant reci

93 Excess 30-day HF readmissions and mortality are present among Black patie

94 ironment modifies the disparity in 30-day HF readmissions and mortality between Black and White patie

95 Excess in composite 30-day HF readmissions and mortality for Black patients ranged fro

96 Excess readmissions and mortality were estimated as the absolut

97 hepatic encephalopathy) and outcomes (30-day readmissions and survival).

98 Primary endpoints included hospital readmissions and total days readmitted.

99 ency department, observation stay, inpatient readmission) and their associated lengths of stay within

100 d Services (CMS) SEP-1 BCx component, 30-day readmission, and all-cause in-hospital and 30-day mortal

101 y of postoperative complications, mortality, readmission, and expenditures.

102 severe complications (Clavien-Dindo >=III), readmission, and in-hospital mortality.

103 ng mortality, any complication, reoperation, readmission, and length of stay.

104 s were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or

105 inpatient admission; discharges, transfers, readmissions, and deaths (trajectories) for 6 months fol

106 over time, less likely to experience 30-day readmissions, and had lower mortality (adjusted hazard r

107 ecificity for predicting adverse events, ICU readmissions, and hospital death.

108 red, as well as severity-adjusted mortality, readmissions, and lengths of stay.

109 tcomes included hospital length of stay, ICU readmissions, and mortality (ICU and hospital).

110 diverge for HF. For AMI and HF, admissions, readmissions, and mortality rates declined over this per

111 heart failure (HF), post-AMI and HF hospital readmissions, and mortality.

112 e, length of stay, emergency department use, readmissions, and mortality.

113 utcomes for the PVI arm: fewer ED visits and readmissions, and shorter initial and total 30-day LOS.

114 everity of illness at ICU admission, and ICU readmission are associated with increased risk of early

115 Late and multiple HF readmissions associate with an increased risk of long-te

116 However, the overall burden of readmissions associated with adhesions remains high.

117 ower all-cause mortality and lower all-cause readmission at 1 year.

118 enal failure were the most common causes for readmission at 30 days.

119 in accountable care organizations to detect readmission at other hospitals.

120 tion index was significantly associated with readmissions (beta, 0.03; p < 0.001).

121 atabase (NRD) to identify patterns of 30-day readmission by patient demographic characteristics and t

122 , 95% CI 0.60-0.77), and of possibly related readmissions by 11% (HR 0.89, 0.85-0.94) compared with o

123 roscopy reduced the risk of directly related readmissions by 32% (hazard ratio [HR] 0.68, 95% CI 0.60

124 We did subgroup analyses of readmissions by anatomical site of surgery and used Kapl

125 Non-index readmission carries a heightened risk of FTR.

126 IRR: 0.14; 95% CI: 0.05-0.37; P < .001), and readmission charges (IRR: 0.11; 95% CI: 0.03-0.46; P = .

127 ere survival and inflation-adjusted hospital readmission charges.

128 a decrease in average proportion of patient readmissions compared to patients discharged on median d

129 d with the best performance and lower 30-day readmissions compared with subspecialty consultation wit

130 information on readmission diagnoses, total readmission costs and factors associated with readmissio

131 e to determine the trends of LT, reasons for readmission, costs and predictors of calendar year morta

132 ntemporary, nationally representative 30-day readmissions data after carotid artery stenting (CAS) an

133 We analyzed 2016 nationwide readmission database (NRD) to identify patterns of 30-da

134 We used the Nationwide Readmissions Database from 2014, which is a nationally r

135 Hospital-level clustering and Nationwide Readmissions Database sampling weights were applied to a

136 After applying the Nationwide Readmissions Database sampling weights, there were 55,62

137 Using the Nationwide Readmissions Database, we identified patients with aorti

138 2010 to September 30, 2015 in the Nationwide Readmissions Database.

139 identified from the 2013 to 2014 Nationwide Readmissions Databases.

140 The present study aimed to examine readmission diagnoses and factors associated with all-ca

141 We estimated the percentage and most common readmission diagnoses for 30-day and 7-day readmissions

142 The spectrum of readmission diagnoses was largely similar in both 30-day

143 Accurate information on readmission diagnoses, total readmission costs and facto

144 Overall, HF readmission did not significantly impact all-cause morta

145 utcome measure was the incidence of hospital readmissions directly related to adhesions in the laparo

146 ms were to examine ERP effect on LOS, 30-day readmission, discharge disposition, and complications.

147 ed length of stay and increased frequency of readmissions due to recurrences.

148 sease were associated with increased risk of readmission during the subsequent year.

149 Spending associated with readmissions, emergency department visits, and outpatien

150 have a significantly higher risk for 30-day readmission following a hospitalization for sepsis.

151 The primary outcome of our study was 30-day readmissions following discharge.

152 -related, respiratory-related, and all-cause readmissions following surgery is unknown.

153 ular events (MACE), all-cause mortality, and readmission for cardiovascular (CV) causes at 3 years' f

154 plications, in-hospital mortality and 30-day readmission for HFrEF compared to HFpEF patients were 1.

155 Readmission for ICU survivor care versus usual care: at

156 Potentially avoidable readmission for severe adverse events and death at 6 mon

157 E) occurred (47 cardiovascular deaths and 89 readmissions for acute heart failure).

158 dhesions, possibly related to adhesions, and readmissions for an operation that was potentially compl

159 t for severe anemia prevented more deaths or readmissions for any reason after discharge than placebo

160 The primary outcome was one or more hospital readmissions for any reason or death from the time of ra

161 -day readmission rate was 2% and the rate of readmission from 30 to 90 days postpartum was 4.6%.

162 The readmission group was older, female predominant, and had

163 Overall, 53 patients (7.1%) experienced late readmissions (>30 days post-TAVR), and 17 (2.3%) had mul

164 propensity matching, patients with non-index readmission had higher rates of FTR (5.6% vs. 4.3%; p <

165 in Ontario, Canada, where reducing hospital readmissions has not had a policy incentive.

166 y associated with the composite of death and readmission (hazard ratio [HR], 1.54; P = .030).

167 ly associated with both incident MACE and CV readmission (hazard ratio [HR]: 0.76; 95% confidence int

168 ons (hazard ratio, 2.25; p < 0.001), and ICU readmission (hazard ratio, 3.76; p < 0.001) as risk fact

169 per 1% increase, 1.010; p < 0.001), and ICU readmission (hazard ratios, 4.10, 4.17, and 1.82 for dea

170 mia, SA children with BWF had higher risk of readmissions (hazard ratio [HR], 1.68; 95% confidence in

171 R, 1.90 [95% CI, 1.30-2.78]) and multiple HF readmissions (HR, 2.10 [95% CI,1.17-3.76]) were signific

172 ce readmission in patients with high risk of readmission identified in our study.

173 ), organ failure in 198 patients (7.6%), and readmission in 427 patients (16.2%).

174 Strategies should be implemented to reduce readmission in patients with high risk of readmission id

175 ernal and fetal outcomes, and cardiovascular readmissions in a cohort of pregnant women with underlyi

176 ) is a leading cause of hospitalizations and readmissions in the United States.

177 yses, monitoring was associated with reduced readmissions (incidence rate ratio [IRR]: 0.56; 95% conf

178 Predictors of non-index readmission included top quartile for zip code median ho

179 care within 30 days of discharge or prior to readmission, including 52% of patients visiting the OPAT

180 to hospital ward and are associated with ICU readmission, increased hospital length of stay and death

181 3 days), but the average number of unplanned readmission inpatient days was 2.0 for SAVR, 3.0 for TAV

182 nts of 90-day episode spending variation are readmissions, inpatient professional fees, and post-acut

183 oring was associated with lower incidence of readmission (IRR: 0.38; 95% CI: 0.23-0.63; P < .001), da

184 Heart failure (HF) readmission is common post-transcatheter aortic valve re

185 HF readmission is common within 1-year of TAVR.

186 eadmission costs and factors associated with readmission is required to effectively plan resource all

187 Reduction of early hospital readmissions is a declared goal in the United States eco

188 rt (n=22 214; 8.4% versus 7.9%, P=0.20), and readmission length of stay was longer for CEA than CAS (

189 pioid exposures were predictive of all-cause readmissions (low: OR 1.09, 95% CI: 1.06-1.12); high: OR

190 2, 95% CI=1.53-1.71] and respiratory-related readmissions [low: aOR=1.10, 95% CI=1.05-1.16; high: aOR

191 associated with higher risk of pain-related readmissions [low: aOR=1.27, 95% CI=1.23-1.32; high: aOR

192 scharge hospital use, rather than the 30-day readmission measure to evaluate health care system perfo

193 if the EDAC measure were used instead of the readmission measure to evaluate performance.

194 t change trend in 30-day readmission (+0.19% readmissions/mo, P=0.554) and trend in 30-day mortality

195 tion (HO-CDI) is a costly problem leading to readmissions, morbidity and mortality.

196 Outcomes [30-day morbidity, unplanned readmissions, mortality, postoperative length of stay (L

197 In ~30% of readmissions, no trigger could be identified.

198 Early readmission not only increases burden on healthcare, but

199 Thirty-day readmission occurred in 9 patients, 7 (8.3%) laparoscopi

200 Multiple readmissions occurred in 739 patients (54%).

201 n remained a significant predictor of 30-day readmission (odds ratio, 1.640 [95% CI, 1.603-1.677], P<

202 ce interval 2.08-4.34), P < 0.01] and 30-day readmissions [odds ratio 1.61 (confidence interval % CI

203 his report describes short-term outcomes and readmissions of patients undergoing HH repair at our ins

204 e (PPH), bile leak, blood loss, reoperation, readmission, oncologic outcomes (R0-resection, lymph nod

205 The lower incidence of readmission or death in the chemoprevention group than i

206 3 through week 26, a total of 184 events of readmission or death occurred in the chemoprevention gro

207 Of these, 9139 were excluded because of readmission or invalid coding.

208 eenness was not associated with any delay in readmission or mortality among AMI and HF patients.

209 nt experiences and no significant changes in readmission or mortality rates.

210 Incidence of readmissions or deaths during the follow-up period was c

211 ismissal group, there were no differences in readmissions or emergency room visits at 30 or 90 days.

212 ital length of stay without increases in ICU readmissions or hospital mortality.

213 inate the Black excess in combined 30-day HF readmissions or mortality in any of the neighborhood qua

214 09 [1.80, 2.43]), and reduced risk of 30-day readmission (OR 0.68 [0.66, 0.70]).

215 96, 95% confidence interval (CI) 0.92-0.99], readmission (OR 0.96, 95% CI 0.93-0.99), and reoperation

216 ty [odds ratio (OR) 1.2, P = 0.004], but not readmission (OR 1.1, P = 0.48) or LOS (incidence rate ra

217 discharge was not associated with decreased readmissions (OR = 1.87; 95% CI, .62-5.10).

218 , reoperation [OR, 0.65 (95% CI, 0.42-1.0)], readmission [OR, 0.82 (95% CI, 0.57-1.2)], and length of

219 LOS, POPF, DGE, PPH, bile leak, reoperation, readmission, or oncologic outcomes between LPD and OPD.

220 as not associated with changes in mortality, readmissions, or length of stay.

221 ntal effects on severity adjusted mortality, readmissions, or lengths of stay.

222 tatistically significant predictor of 90-day readmission (p = 0.03).

223 ndex hospitalization (-16.7%, P = 0.002) and readmissions payments (-27.0%, P = 0.003).

224 yments related to the index hospitalization, readmissions, physician services, and postacute care.

225 k-adjusted 30-day home time had lower 30-day readmission (quartile 1 versus 4, 21% versus 17%), 30-da

226 gth of stay (6.5 versus 3.2 days, P < 0.01), readmission rate (29.1% vs 3.1%, P < 0.01), and discharg

227 The utility of 30-day risk-standardized readmission rate (RSRR) as a hospital performance metric

228 The 30-day readmission rate after hospitalization for a sickle cell

229 nding hospitals had an average risk-adjusted readmission rate of 17.3% compared to 29.4% in the highe

230 Following delivery, 30-day readmission rate was 2% and the rate of readmission from

231 The 30-day readmission rate was 30.6% among a total of 25,054 LTRs.

232 The 180-day readmission rate was 62.3% in the intervention group and

233 The overall 30-day readmission rate was higher before the intervention than

234 In all operations, the risk-adjusted readmission rate was lower among the lowest-spending hos

235 ates at the cost of a slightly higher 30-day readmission rate.

236 e treatment of ABSSSI, with a higher 30-days readmission rate.

237 no significant differential change in 30-day readmission rates (-0.10 percentage points; 95% CI, -0.5

238 ation, ED visit, post-acute utilization, and readmission rates (P < 0.001).

239 Readmission rates after acute myocardial infarction (AMI

240 recorded to determine their relationship to readmission rates and other healthcare outcomes.

241 (aOR, 1.31 [95% CI, 1.02-1.68]), but 30-day readmission rates did not differ.

242 team, maternal outcomes were encouraging and readmission rates following delivery were low.

243 Thirty-day readmission rates for the weighted 232,852 HF patients w

244 ) has penalized hospitals with higher 30-day readmission rates more than $3 billion to date.

245 stay was 4 days shorter and 30-day hospital readmission rates were 48% lower in the exebacase-treate

246 Readmission rates were higher after RYGB (4.3% vs 3.4%,

247 Crude 30-day readmission rates were higher for patients treated with

248 with very high use of health care services, readmission rates were not lower among patients randomly

249 ay-case care bundles to reduce high hospital readmission rates with greater care in the community is

250 ary family caregivers, and assess mortality, readmission rates, and economic impact compared with usu

251 s no statistically significant difference in readmission rates.

252 nces in parenteral antibiotic completion and readmission rates.

253 associated with high mortality and hospital readmission rates.

254 location and to plan interventions to reduce readmission rates.

255 ission were neurological and cardiac events; readmission reasons varied by revascularization modality

256 emote monitoring may be useful in preventing readmissions, reducing subsequent inpatient days, and co

257 The Hospital Readmissions Reduction Program (HRRP) has penalized hosp

258 We started an AMI readmissions reduction program in November 2017.

259 An AMI readmissions reduction program that increases outpatient

260 tes since the implementation of the Hospital Readmissions Reduction Program.

261 ut potential adverse effects and efficacious readmission-reduction strategies are not well validated.

262 r early discharge is associated with patient readmissions remains controversial.

263 ted appendicitis, return to baseline health, readmission, reoperation, unplanned appendectomy, advers

264 ient mortality or live discharge, and 30-day readmission risk using bivariable Poisson, Fine-Gray, an

265 Thirty-day readmission risk was 18.9% (95% CI, 17.7%-20.2%), stable

266 In a multivariate analysis, 90-day readmission risk was higher among PWID who did not recei

267 y total spending on LEJR episodes and 90-day readmissions; secondary outcomes were postacute spending

268 pitalization, physician, postacute care, and readmission spending was analyzed.

269 Primary outcomes were 30 day readmissions, surgical complications, medical complicati

270 an inform potential interventions to prevent readmissions through OPAT clinic follow-up and to furthe

271 Readmission to a different hospital leads to fragmentati

272 Readmission to hospital and/or a repeat intervention was

273 tient outcomes including hospital mortality, readmission to ICU, and length of hospital stay after IC

274 The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted pat

275 Thirty-day readmission was identified through hospital billing data

276 Non-index readmission was independently associated with higher odd

277 For HF, overall risk-adjusted 30-day readmission was largely unchanged from 2006 to 2014 at 2

278 act of individual complications on unplanned readmission was smaller than 11%.

279 Patient readmission was stratified by 6 operative groups.

280 association between quality performance and readmissions was sensitive to changes in methodology but

281 ositive predictive values for 30- and 90-day readmission were 14.8% and 26.2%, respectively, and nega

282 The most common reasons for readmission were neurological and cardiac events; readmi

283 Readmissions were categorised as directly related to adh

284 Predominant causes of readmissions were changes in medication/nonadherence and

285 acteristics, contextual-level variables, and readmissions were compared by t tests for continuous var

286 The majority of 30-day readmissions were due to post transplant complications,

287 Among patients hospitalized for SCC, 30-day readmissions were frequent throughout the month post hos

288 0.004), but differences in changes in 90-day readmissions were not significant (adjusted DID, -0.47 p

289 ADR-related hospital readmissions were similar in both groups (2.1 and 2.2%).

290 pital stay (>75th percentile), and unplanned readmission), whereas adjusting for confounders and othe

291 s home may reduce cost, health care use, and readmissions while improving patient experience, althoug

292 alization reduced cost, health care use, and readmissions while increasing physical activity compared

293 was largely similar in both 30-day and 7-day readmission with more than 80% patients in both time per

294 the incidence, predictors, and impact of HF readmission within 1-year post-TAVR, and assessed the ef

295 The primary outcome was hospital readmission within 180 days after discharge.

296 infection have a high likelihood of death or readmission within 23 months.

297 med influenza, there is a high likelihood of readmission within 30 days and 1 year adding to the morb

298 AT clinic would reduce the risk for hospital readmission within 30 days.

299 sfully treated, defined as no ABSSSI-related readmission within 30-days after the initiation of treat

300 severe complications, mortality, and rate of readmissions within 30 days), and 1-year results (follow